DeSimone Jill 4

What Happened

• Jill DeSimone, a director of Praxis Precision Medicines (PRAX), received equity awards on 2026-06-10: 1,371 restricted stock units (RSUs) and 648 derivative units, for a total potential 2,019 shares. Both grants were reported as acquisitions at $0 (they are awards, not purchases).

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Price: $0.00 (awards/grants — no cash exchanged at grant).
• Vesting:
  • 1,371 RSUs vest in a single installment on the earlier of June 10, 2027 or the date of the 2027 annual meeting; settlement only in common stock (per footnote).
  • 648-unit derivative award vests in 12 equal monthly installments on the 10th of each month starting July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting (per footnote).
• Shares owned after the transaction: not disclosed in this filing.
• Filing accession: 0001689548-26-000061; Period of Report: 2026-06-10.

Context

• These are compensation awards (RSUs/derivative units) that convert to actual shares only as they vest; they are common director compensation and do not represent an open‑market purchase or sale.
• Because the awards were granted (not sold or bought), they are not a direct bullish or bearish trading signal by themselves.